Gemcitabine Kabi gemcitabine (as hydrochloride) 2000 mg/52.6 mL concentrated solution for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

gemcitabine kabi gemcitabine (as hydrochloride) 2000 mg/52.6 ml concentrated solution for injection vial

fresenius kabi australia pty ltd - gemcitabine hydrochloride, quantity: 2277.2 mg (equivalent: gemcitabine, qty 2000 mg) - injection, concentrated - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - gemcitabine kabi is indicated for treatment of patients with locally advance or metastatic non-small cell lung cancer. gemcitabine kabi is indicated for treatment of patients with locally advance or metastatic adenocarcinoma of the pancreas. gemcitabine is also indicated for patients with 5-fu refractory pancreatic cancer. gemcitabine kabi, alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer. gemcitabine kabi, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. gemcitabine kabi, in combinatin with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum-based therapy.

Gemcitabine Kabi gemcitabine (as hydrochloride) 1000 mg/26.3 mL concentrated solution for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

gemcitabine kabi gemcitabine (as hydrochloride) 1000 mg/26.3 ml concentrated solution for injection vial

fresenius kabi australia pty ltd - gemcitabine hydrochloride, quantity: 1138.6 mg (equivalent: gemcitabine, qty 1000 mg) - injection, concentrated - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - gemcitabine kabi is indicated for treatment of patients with locally advance or metastatic non-small cell lung cancer. gemcitabine kabi is indicated for treatment of patients with locally advance or metastatic adenocarcinoma of the pancreas. gemcitabine is also indicated for patients with 5-fu refractory pancreatic cancer. gemcitabine kabi, alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer. gemcitabine kabi, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. gemcitabine kabi, in combinatin with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum-based therapy.

Gemcitabine Kabi gemcitabine (as hydrochloride) 200 mg/5.26 mL concentrated solution for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

gemcitabine kabi gemcitabine (as hydrochloride) 200 mg/5.26 ml concentrated solution for injection vial

fresenius kabi australia pty ltd - gemcitabine hydrochloride, quantity: 227.72 mg (equivalent: gemcitabine, qty 200 mg) - injection, concentrated - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - gemcitabine kabi is indicated for treatment of patients with locally advance or metastatic non-small cell lung cancer. gemcitabine kabi is indicated for treatment of patients with locally advance or metastatic adenocarcinoma of the pancreas. gemcitabine is also indicated for patients with 5-fu refractory pancreatic cancer. gemcitabine kabi, alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer. gemcitabine kabi, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. gemcitabine kabi, in combinatin with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum-based therapy.

DOCETAXEL KABI docetaxel anhydrous 160 mg/8 mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

docetaxel kabi docetaxel anhydrous 160 mg/8 ml concentrated injection vial

fresenius kabi australia pty ltd - docetaxel, quantity: 160 mg - injection, concentrated - excipient ingredients: citric acid; polysorbate 80; ethanol absolute - breast cancer,metastatic breast cancer,docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed.,docetaxel in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.,docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease.,adjuvant treatment of breast cancer,docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node-positive breast cancer.,doxorubicin and cyclophosphamide followed by docetaxel in combination with trastuzumab (acth) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2.,docetaxel in combination with carboplatin and trastuzumab (tch) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2.,docetaxel in combination with cyclophosphamide is indicated for the adjuvant treatment of operable breast cancer with a primary tumour of ?1cm and <7cm.,non small cell lung cancer,docetaxel is indicated for the treatment of patients with locally advanced or metastatic non small cell lung cancer, including those who have failed platinum-based chemotherapy.,ovarian cancer,docetaxel is indicated for the treatment of metastatic carcinoma of the ovary after failure of firstline or subsequent chemotherapy.,prostate cancer,docetaxel is indicated for the treatment of patients with androgen independent (hormone refractory) prostate cancer.,head and neck cancer,docetaxel, in combination with cisplatin and fluorouracil is indicated as induction treatment prior to chemoradiotherapy, for the treatment of patients with locally advanced, squamous cell carcinoma of the head and neck, who have low probability of surgical cure, require organ preservation or where the tumour is technically unresectable.

DOCETAXEL KABI docetaxel anhydrous 20 mg/1 mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

docetaxel kabi docetaxel anhydrous 20 mg/1 ml concentrated injection vial

fresenius kabi australia pty ltd - docetaxel, quantity: 20 mg - injection, concentrated - excipient ingredients: citric acid; polysorbate 80; ethanol absolute - breast cancer,metastatic breast cancer,docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed.,docetaxel in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.,docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease.,adjuvant treatment of breast cancer,docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node-positive breast cancer.,doxorubicin and cyclophosphamide followed by docetaxel in combination with trastuzumab (acth) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2.,docetaxel in combination with carboplatin and trastuzumab (tch) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2.,docetaxel in combination with cyclophosphamide is indicated for the adjuvant treatment of operable breast cancer with a primary tumour of ?1cm and <7cm.,non small cell lung cancer,docetaxel is indicated for the treatment of patients with locally advanced or metastatic non small cell lung cancer, including those who have failed platinum-based chemotherapy.,ovarian cancer,docetaxel is indicated for the treatment of metastatic carcinoma of the ovary after failure of firstline or subsequent chemotherapy.,prostate cancer,docetaxel is indicated for the treatment of patients with androgen independent (hormone refractory) prostate cancer.,head and neck cancer,docetaxel, in combination with cisplatin and fluorouracil is indicated as induction treatment prior to chemoradiotherapy, for the treatment of patients with locally advanced, squamous cell carcinoma of the head and neck, who have low probability of surgical cure, require organ preservation or where the tumour is technically unresectable.

DOCETAXEL KABI docetaxel anhydrous 80 mg/4 mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

docetaxel kabi docetaxel anhydrous 80 mg/4 ml concentrated injection vial

fresenius kabi australia pty ltd - docetaxel, quantity: 80 mg - injection, concentrated - excipient ingredients: ethanol absolute; polysorbate 80; citric acid - breast cancer,metastatic breast cancer,docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed.,docetaxel in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.,docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease.,adjuvant treatment of breast cancer,docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node-positive breast cancer.,doxorubicin and cyclophosphamide followed by docetaxel in combination with trastuzumab (acth) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2.,docetaxel in combination with carboplatin and trastuzumab (tch) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2.,docetaxel in combination with cyclophosphamide is indicated for the adjuvant treatment of operable breast cancer with a primary tumour of ?1cm and <7cm.,non small cell lung cancer,docetaxel is indicated for the treatment of patients with locally advanced or metastatic non small cell lung cancer, including those who have failed platinum-based chemotherapy.,ovarian cancer,docetaxel is indicated for the treatment of metastatic carcinoma of the ovary after failure of firstline or subsequent chemotherapy.,prostate cancer,docetaxel is indicated for the treatment of patients with androgen independent (hormone refractory) prostate cancer.,head and neck cancer,docetaxel, in combination with cisplatin and fluorouracil is indicated as induction treatment prior to chemoradiotherapy, for the treatment of patients with locally advanced, squamous cell carcinoma of the head and neck, who have low probability of surgical cure, require organ preservation or where the tumour is technically unresectable.

SMOFKABIVEN EMULSION Canada - English - Health Canada

smofkabiven emulsion

fresenius kabi canada ltd - fish oil; dextrose; lysine (lysine acetate); phenylalanine; leucine; valine; threonine; methionine; isoleucine; tryptophan; alanine; arginine; glycine; proline; histidine; serine; taurine; tyrosine; sodium acetate trihydrate; potassium chloride; sodium glycerophosphate; magnesium sulfate; calcium chloride; zinc sulfate heptahydrate; soybean oil; medium chain triglycerides (mct); olive oil - emulsion - 0.57g; 12.7g; 0.34g; 0.26g; 0.38g; 0.31g; 0.22g; 0.22g; 0.25g; 0.1g; 0.71g; 0.61g; 0.56g; 0.57g; 0.15g; 0.33g; 0.05g; 0.02g; 0.17g; 0.23g; 0.21g; 0.061g; 0.028g; 0.00066g; 1.14g; 1.14g; 0.95g - fish oil 0.57g; dextrose 12.7g; lysine (lysine acetate) 0.34g; phenylalanine 0.26g; leucine 0.38g; valine 0.31g; threonine 0.22g; methionine 0.22g; isoleucine 0.25g; tryptophan 0.1g; alanine 0.71g; arginine 0.61g; glycine 0.56g; proline 0.57g; histidine 0.15g; serine 0.33g; taurine 0.05g; tyrosine 0.02g; sodium acetate trihydrate 0.17g; potassium chloride 0.23g; sodium glycerophosphate 0.21g; magnesium sulfate 0.061g; calcium chloride 0.028g; zinc sulfate heptahydrate 0.00066g; soybean oil 1.14g; medium chain triglycerides (mct) 1.14g; olive oil 0.95g - replacement preparations

PEDITRACE zinc copper manganese selenium fluorine and iodine injection solution United States - English - NLM (National Library of Medicine)

peditrace zinc copper manganese selenium fluorine and iodine injection solution

fresenius kabi usa, llc - zinc chloride (unii: 86q357l16b) (zinc cation - unii:13s1s8sf37) - zinc cation 250 ug in 1 ml

PACLITAXEL KABI paclitaxel 300 mg/50 mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

paclitaxel kabi paclitaxel 300 mg/50 ml concentrated injection vial

fresenius kabi australia pty ltd - paclitaxel, quantity: 300 mg - injection, concentrated - excipient ingredients: ethanol; citric acid; peg-35 castor oil - primary treatment of ovarian cancer in combination with a platinum agent. treatment of metastatic carcinoma of the ovary after failure of standard therapy. treatment of metastatic carcinoma of the breast after failure of standard therapy. adjuvant treatment of node-positive breast cancer administered sequentially to doxorubicin and cyclophosphamide. treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metastatic disease. in combination with gemcitabine (gemzar), the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. treatment of non-small cell lung cancer (nsclc).

PACLITAXEL KABI paclitaxel 100 mg/16.7 mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

paclitaxel kabi paclitaxel 100 mg/16.7 ml concentrated injection vial

fresenius kabi australia pty ltd - paclitaxel, quantity: 100.2 mg - injection, concentrated - excipient ingredients: ethanol; peg-35 castor oil; citric acid - primary treatment of ovarian cancer in combination with a platinum agent. treatment of metastatic carcinoma of the ovary after failure of standard therapy. treatment of metastatic carcinoma of the breast after failure of standard therapy. adjuvant treatment of node-positive breast cancer administered sequentially to doxorubicin and cyclophosphamide. treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metastatic disease. in combination with gemcitabine (gemzar), the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. treatment of non-small cell lung cancer (nsclc).